Healthcare 02 (May 15 - Dec 25)

[winston]

7 Healthcare Stocks to Buy for Your Retirement

With demand for healthcare surging, now is the time to buy for the long term

By Aaron Levitt

Source: Investor Place

http://investorplace.com/2016/04/health ... wXODKR96M8

[winston]

U.S. prescription drug spending to hit $400 billion a year by 2020: IMS

BY BILL BERKROT

"Our spending on those drugs will be relatively high but still manageable ... because they will be offset by more modest price increases for branded drugs and a rising level of savings from drugs losing patent protection," Aitken said.

Upcoming high-profile patent expirations include AstraZeneca's Crestor and Pfizer Inc's Lyrica and Viagra.

By 2020, there will also be increased competition from cheaper versions of pricey biotech medicines, known as biosimilars. The U.S. Food and Drug Administration has so far approved two biosimilars, with many more in development.

In 2015, generic drugs, including off-patent medicines still sold under brand names, accounted for nearly 89 percent of all prescriptions filled, IMS reported.

Source: Reuters

http://www.reuters.com/article/us-healt ... h%20Report

[winston]

The Only Sector You Should Buy Today

By Jeff Clark

It's time to buy biotech stocks.

While nearly every other sector of the market is trading near highs for the year, the biotech sector is still down 10% in 2016. It's down 40% from its peak last summer.

The broad stock market rally over the past seven weeks has pushed the S&P 500 up 17% from its February low. The semiconductor sector is almost 20% higher. Technology stocks are up 15%. And even the banking sector played "catch-up" last week with a solid move higher.

Most of the biotech stocks have missed the party.

But that may be about to change. While the rest of the market is overbought and most of the sector charts look "toppy," the biotech sector appears to be set up for a rally.

Take a look at this chart of the SPDR S&P Biotech Fund (XBI), an exchange-traded fund that holds about 90 companies in the sector...

Please Enable Images to See this

Three weeks ago, the fund's nine-day exponential moving average (EMA) – shown in red on the chart – crossed above its 50-day moving average (DMA) line – shown in blue. This "bullish cross" is often the first sign of a new rally phase. As you can see, XBI has performed well so far this month.

But the sector is still down almost 20% from where it started the year. So there's plenty of upside remaining in this move. If XBI can break above the first resistance level at about $59 per share, then it could spark a quick rally toward one of the upper resistance levels at either $64 or $72.

On the downside, XBI has support at its nine-day EMA – which is currently at about $56. There's more support at the 50-DMA – near $51. If the sector is indeed in the early stages of an intermediate-term rally, XBI should not break below $51.

Aggressive traders can set up a good risk/reward position by buying XBI right here at $57, setting a downside stop at $51, and holding out for an upside target of $72.

Get in while you can and enjoy the rally.

Source: Growth Stock Wire

[winston]

Health care bull market continues... Medtronic, Thermo Fisher, Baxter, and Edwards Lifesciences hit 52-week highs.

[winston]

Big Pharma giant Bristol-Myers Squibb breaks out to multiyear high... up 20% since early February.

[winston]

Biotech starts to recover… sector fund XBI is up nearly 30% since mid-February.

[winston]

3 Healthcare Stocks Under the Microscope

Heightened scrutiny will potentially dampen enthusiasm as VRX, PRGO and ABBV release earnings

By Josh Enomoto

Source: Investor Place

http://investorplace.com/2016/04/health ... yBRqfl96M8

[winston]

HEALTH CARE STOCKS HIT ALL-TIME HIGHS

The aging U.S. population is leading health care stocks to new highs...

For many years, our colleague David Eifrig has told his readers to invest in the health care sector. His thesis is simple: He believes the money spent for treatment will continue to grow as Baby Boomers get older.

Lately, two health care companies have been in steady uptrends: Medtronic (MDT) and Baxter International (BAX). Medtronic is the world's largest maker of medical devices like insulin pumps and pacemakers. Baxter makes systems for treating patients with a range of conditions, including hemophilia and kidney disease.

As you can see in the chart below, shares of Medtronic (black line) and Baxter (blue line) are up 22% and 35%, respectively, since late September. It's even more proof that Doc's health care thesis is spot on.

Source: Daily Wealth

[winston]

3 Great ETFs for a Biotech Rebound – BBP CNCR XBI

Biotech stocks and ETFs are rebounding, and these can help you play that resurgence

While diversified healthcare ETFs are sporting small year-to-date gains or modest losses, and some healthcare industry ETFs are thriving, biotech ETFs are still saddled with deep double-digit losses.

That is the bad news. The good news is that while biotech stocks and ETFs might not notch the boffo performances seen in 2013 or 2014, the group has recently been rebounding in impressive fashion.

By Todd Shriber

Source: Investor Place

http://investorplace.com/2016/05/best-e ... yg8Nvl96M8

[winston]

Charts are bullish for health care: Technician

By Lawrence Lewitinn

Source: Yahoo Finance

http://finance.yahoo.com/news/charts-ar ... 49912.html